Based in Riga, the Baltics, Grindeks is a vertically integrated pharmaceutical company with the history from 1946. Its main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients.
The company specializes in the heart and cardiovascular, CNS, anti-cancer and anti-diabetes medicines.
The Grindeks’ Group consists of 4 subsidiary companies in Latvia, Estonia and Slovakia; representative offices are opened in 11 countries.
Grindeks’ products are exported to more than 80 countries with export comprising 93,3 % of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam.